Loading stock data…
$6.42-0.47 (-6.80%)
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Immunic, Inc. in the Healthcare sector is trading at $6.43 with a market capitalization of $145M. Wall Street consensus targets $43.09 (11 analysts), implying a +570.1% move over the next 12 months. The stock is currently near its 52-week low of $5.06, remaining 43.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$35.33M↓ | -$33.23M↓ | -$23.33M↑ | -$25.99M↑ | -$27.08M |
| Net Income | -$34.10M↓ | -$32.59M↓ | -$19.30M↑ | -$25.58M↑ | -$26.82M |
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is i...